Contact Us
Website
Legal
Privacy
Cookie Notice
The Global Top 10 Risks
Life Sciences
Findings from Aon’s 2021 Global Risk Management Survey
Explore the Full Interactive Report >
Top Risks by Region
Explore the Full Interactive Report >
North America
Latin America
Europe
Middle East & Africa
Asia Pacific
Top 3 Risks
1. Cyber Attacks/Data Breach
2. Business Interruption
3. Damage to Reputation/Brand
Top 3 Risks
1. Economic Slowdown/Slow Recovery
2. Business Interruption
3. Commodity Price Risk/Scarcity of Materials
Top 3 Risks
1. Business Interruption
2. Commodity Price Risk/Scarcity of Materials
3. Economic Slowdown/Slow Recovery
Top 3 Risks
2. Cyber Attacks/Data Breach
3. Business Interruption
1. Economic Slowdown/Slow Recovery
Top 3 Risks
2. Cyber Attacks/Data Breach
1. Business Interruption
3. Economic Slowdown/Slow Recovery
D&O for Life Sciences: Taking Back Control in a Challenging Market
D&O remains a critical concern for life sciences organisations, with tough market conditions meaning early renewal discussions are more important than ever.
Life sciences organisations are looking to digitalisation to revolutionise drug discovery and research, clinical trials, manufacturing and operations, sales and marketing and supply
chain and distribution – shaping a new risk landscape.
Cell and gene treatments are presenting major growth opportunities for the sector, while revolutionising therapies and commercial strategies.
Meanwhile, there are opportunities for the life sciences industry to pursue growth in emerging and sizable markets - in particular China. The entry hurdles can be significant and organisations need to carefully consider their changing risk profile.
Finally, life sciences organisations are facing increasing competition from adjacent sectors such as agrichemical and technology as the nature and requirements of patient treatment evolve.
To receive Aon's EMEA industry insights straight to your inbox
Navigating Patent Risks for Medical Technology Firms
Patent litigations in the medical technology industry are frequent, often result in significant damages and settlements, and last longer compared to other sectors.
Learn More
Learn More
Sign Up
Future of Risk Video
Find out more about... The nature of companies’ key assets and potential vulnerabilities has evolved. It’s time for a new approach to due diligence.
Featured Insights
Four key trends will continue to shape the pharma & life sciences industry in the years ahead:
1. Digitalisation
2. Innovative treatments and pricing
3. Emerging market growth
4. Navigating the competitive landscape
Learn More
Demand for Talent Set to Surge in 2022 for Life Sciences
Although 71% of life sciences firms plan to increase their workforce, an industry-wide skills shortage is increasing demand for talent.
How can firms reassess and adjust their human capital strategy to attract and retain critical skills in 2022 and beyond?
Learn More
Aon talks with ADC Therapeutics about innovation in the cancer treatment space, their recent IPO and the challenges of attracting and retaining top talent.
In Conversation With
ADC Therapeutics
Greg Case
Industry Leader Here
AON
Click to email >
Learn More
Unlocking Market Access Through Insurance
By partnering with insurers, pharmaceutical and biotech firms can increase market access to specialist and high-cost treatments, which might otherwise be out of reach for certain patients and markets.
Learn More
Medical IoT devices are now the centre of attention for a healthcare industry grappling with new and complex cyber exposures.
Cyber Security of IoT Medical Devices
Home
Read More Insights
Read More Insights
Life Sciences
Four key trends will continue to shape the pharma & life sciences industry in the years ahead:
1. Digitalisation
2. Innovative treatments and pricing
3. Emerging market growth
4. Navigating the competitive landscape
Home
Life sciences organisations are looking to digitalisation to revolutionise drug discovery and research, clinical trials, manufacturing and operations, sales and marketing and supply
chain and distribution – shaping a new risk landscape.
Cell and gene treatments are presenting major growth opportunities for the sector, while revolutionising therapies and commercial strategies.
Meanwhile, there are opportunities for the life sciences industry to pursue growth in emerging and sizable markets - in particular China. The entry hurdles can be significant and organisations need to carefully consider their changing risk profile.
Finally, life sciences organisations are facing increasing competition from adjacent sectors such as agrichemical and technology as the nature and requirements of patient treatment evolve.
Contact Us
Website
Legal
Privacy
Cookie Notice
Sign up to receive insights in your inbox >
Learn More
Life Sciences M&A:
A Bullish Outlook
COVID-19 has placed the life sciences industry front-and-centre, but the hunt for vaccines and therapeutic cures are not without pitfalls for those involved. This loads additional risk considerations on any M&A plans.
Learn More
COVID-19 has placed the life sciences industry front-and-centre, but the hunt for vaccines and therapeutic cures are not without pitfalls for those involved. This loads additional risk considerations on any M&A plans.
Life Sciences M&A:
A Bullish Outlook
Learn More
Demand for Talent Set to Surge in 2022 for Life Sciences
Although 71% of life sciences firms plan to increase their workforce, an industry-wide skills shortage is increasing demand for talent.
How can firms reassess and adjust their human capital strategy to attract and retain critical skills in 2022 and beyond?
Learn More
A company’s reputation needs to be actively managed like any other core asset and for Life Sciences firms the issue is particularly critical. Drawing on insights from Pentland Analytics, this report explores reputational risk crises and their implications.
Building reputational resilience
Learn More
Future Skills and Talent Resilience
COVID-19 has sharpened the focus of life sciences organizations on future skills and securing stand-out talent, as they consider a broadening set of factors to attract and retain the best.
Learn More
COVID-19 has sharpened the focus of life sciences organizations on future skills and securing stand-out talent, as they consider a broadening set of factors to attract and retain the best.
Future Skills and
Talent Resilience
Learn More
Medical IoT devices are now the centre of attention for a healthcare industry grappling with new and complex cyber exposures.
Cyber Security of IoT Medical Devices
Learn More
A company’s reputation needs to be actively managed like any other core asset and for Life Sciences firms the issue is particularly critical. Drawing on insights from Pentland Analytics, this report explores reputational risk crises and their implications.
Building Reputational Resilience